



Suite 518, Level 5
165-167 Phillip Street
Sydney NSW Australia 2000

PO Box H100
Australia Square NSW Australia 1215

T +61 2 8098 0819

F +61 2 8080 8315

www.mmjphytotech.com.au

info@mmjphytotech.com.au

ABN 91 601 236 417

ASX RELEASE

27 September 2018

Bien to establish cannabis derivatives manufacturing facility

MMJ PhytoTech Limited (ASX: MMJ) ("MMJ") is pleased to note the attached media release confirming that Bien Ventures Ltd. ("Bien") aims to establish a cannabis derivatives manufacturing facility in Calgary AB in which it will develop proprietary intellectual property ("IP") for nanoemulsions and powdered forms of CBD and THC.

MMJ's CEO Jason Conroy commented that "We are pleased that Bien has withdrawn its resources from test marketing in California and turned its focus to developing proprietary IP at a time when a number of Canadian Licensed Producers are actively looking for development partners, particularly in the cannabis edibles segment."

MMJ owns 13.7% of Bien.

Investor and Media Enquiries

Jason Conroy
Chief Executive Officer

About MMJ

MMJ is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: <https://www.mmjphytotech.com.au/investors/>

Important Notice

This announcement contains reference to certain intentions, expectations, future plans, strategy and prospects of MMJ. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of MMJ may be influenced by a number of factors, many of which are outside the control of MMJ. No representation or warranty, express or implied, is made by MMJ, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause MMJ's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. MMJ does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in MMJ. This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). MMJ's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.



Bien to Establish Cannabis Derivatives Manufacturing Facility

CALGARY, Alberta – September 26, 2018 – Bien Ventures Ltd. (“Bien”) is pleased to announce that it is to establish a cannabis derivatives manufacturing facility in Calgary, Alberta, subject to licensing by Health Canada and municipal approval.

The existing facility includes a fully-equipped prototyping lab with comprehensive testing capabilities through which Bien aims to develop proprietary formulations of nanoemulsions and powdered forms of CBD, THC and a wide range of other organic loads such as terpenes. Bien’s products will focus on rapid effect onset, enhanced bioavailability, discreet delivery, consistency and stability.

Bien has submitted an ACMPR Licensed Producer application to Health Canada in compliance with the expected future requirements for a Standard Processing Licence.

Bien has also commenced discussions with Canadian Licensed Producers and food and beverage brands that plan to bring cannabis edibles and beverages to market when the regulations for such products are set by Health Canada.

For more information please contact:

Andrew Wong, CSO

Telephone: 1-403-472-0549

Email: info@bienbrands.com

About Bien

Bien is focused on the research, development and pharmaceutical-grade manufacturing of next-generation cannabis products for infusion or direct consumption with an emphasis on tailoring dosage, onset time, duration and bioavailability profiles. Balancing academia and industry, our team of technical experts is dedicated to continually improving our processes and formulations to bring best-in-class input solutions for those wanting to develop or improve their existing cannabis product portfolio.